Infliximab for the treatment of fistulas in patients with Crohn's disease

New England Journal of Medicine

Volumn 340, Issue 18, 1999, Pages 1398-1405

  Present, Daniel H ^a,i   Rutgeerts, Paul ^b   Targan, Stephan ^c   Hanauer, Stephen B ^d   Mayer, Lloyd ^a   Van Hogezand, R A ^e   Podolsky, Daniel K ^f   Sands, Bruce E ^f   Braakman, Tanja ^g   Dewoody, Kimberly L ^g   Schaible, Thomas F ^g   Van Deventer, Sander J H ^h  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g CENTOCOR INC   (United States)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; DNA ANTIBODY; DOUBLE STRANDED DNA; INFLIXIMAB; MONOCLONAL ANTIBODY; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABSCESS; ADULT; ANUS FISTULA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENTEROCUTANEOUS FISTULA; FATIGUE; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; CUTANEOUS FISTULA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTESTINAL FISTULA; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0033529049     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199905063401804     Document Type: Article

References (26)

1. Williams DR, Collier JA, Corman ML, Nugent FW, Veidenheimer MC. Anal complications in Crohn's disease. Dis Colon Rectum 1981;24:22-4.
2. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease: a meta-analysis. Ann Intern Med 1995;123:132-42.
3. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 1980;302:981-7.
4. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol 1993;88:646-9.
5. van Deventer SJH. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443-8.
6. Brynskov J, Nielsen OH, Ahnfelt-Ronne I, Bendtzen K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review. Dig Dis 1994;12:290-304.
7. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
8. Reimund J-M, Wittersheim C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996;16:144-50.
9. Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-66.
10. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
11. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
12. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995;7:251-9.
13. Siegel SA, Shealy DJ, Nakada MT, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995;7:15-25.
14. McCabe RP, Woody J, van Deventer S, et al. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease. Gastroenterology 1996;110:Suppl:A962. abstract.
15. van Dullemen HM, van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
16. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997;337:1029-35.
17. Rutgeerts P, D'Haens G, van Deventer SJH, et al. Retreatment with anti-TNF-α chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease. Gastroenterology 1997;112:Suppl:A1078. abstract.
18. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
19. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index: McMaster IBD Study Group. J Clin Gastroenterol 1995;20:27-32.
20. Buyse ME, Staquet MJ, Sylvester RJ, eds. Cancer clinical trials: methods and practice. Oxford, England: Oxford University Press, 1984: 267-9.
21. Bernstein LH, Frank MS, Branch LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980;79:357-65.
22. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982;83: 383-7.
23. Solomon MJ, McLeod RS, O'Connor BI, Steinhart AH, Greenberg GR, Cohen Z. Combination ciprofloxacin and metronidazole in severe perianal Crohn's disease. Can J Gastroenterol 1993;7:571-3.
24. Mahadevan U, Marion JF, Present DH. The place for methotrexate in the treatment of refractory Crohn's disease. Gastroenterology 1997;112: Suppl:A1031. abstract.
25. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci 1994;39:374-80.
26. Greenstein AJ, Mullin GE, Strauchen JA, et al. Lymphoma in inflammatory bowel disease. Cancer 1992;69:1119-23.